Synthesis of 177Lu-based bioconjugate for radioimmunotherapy and evaluation of its stability in physiological media

详细

Labeling of the conjugated molecule of human serum albumin (HSA) and humanized scFv 4D5 mini-antibody specific to her-2/neu receptor with β-emitting ¹⁷⁷Lu radionuclide via p-SCN-benzyl-DTPA chelator was studied. The radioconjugate can be prepared with the decay-corrected radiochemical yield of 82%. The stability of the synthesized complex in physiological solutions (normal saline, human blood serum) was evaluated. The complex is stable in physiological solutions for no less than 10 days.